Navigation Links
Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015
Date:1/28/2016

LONDON, Jan. 28, 2016 /PRNewswire/ -- Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015

Summary

GlobalData's clinical trial report, "Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2015" provides an overview of Heterozygous familial hypercholesterolemia (heFH) clinical trials scenario. This report provides top line data relating to the clinical trials on Heterozygous familial hypercholesterolemia (heFH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Download the full report: https://www.reportbuyer.com/product/3576987/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com


'/>"/>
SOURCE ReportBuyer
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy
2. Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
3. ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
4. Isis Reports Phase 2 Data on ISIS-APOCIII Rx Showing Substantial Reductions of Triglycerides and Apoc-III in Patients with Familial Chylomicronemia
5. Viking Therapeutics Submits Investigational New Drug (IND) Application to Conduct Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Fatty Liver Disease
6. PCSK9 and Other Novel Hypercholesterolemia Drugs
7. Global Hypercholesterolemia Market 2014-2018
8. Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia
9. Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
10. Global Liquid Biopsy Markets Market Report 2016-2020 - Blood Tests Replace Surgical Biopsies / Single Screening Test for all Cancers Announced
11. Disposable Syringes Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2019)... N.Y. (PRWEB) , ... May 22, 2019 , ... ... of AMI MEDITATION reversed his diagnosed condition of burnout at the American ... other health care providers, October 22-26, 2019 at the Cranwell Resort and Spa ...
(Date:5/21/2019)... ... May 21, 2019 , ... On May 18th, 2019, LuckyVitamin ... with Girls on the Run, a non-profit organization that offers after-school programs for girls ... PA. , As part of a successful day of inspiring and bolstering young ...
(Date:5/21/2019)... ... May 21, 2019 , ... Ziegler, a ... advisor to Greensboro Radiology on its partnership with Radiology Partners. , Greensboro Radiology ... over a span of ~20 years, and is ranked among the top 30 ...
Breaking Medicine Technology:
(Date:5/22/2019)... ... May 22, 2019 , ... ... health observance, National Lifestyle Medicine Week, to take place May 28 to June ... evidence-based therapeutic approaches of Lifestyle Medicine: a whole food, plant-predominant dietary lifestyle, regular ...
(Date:5/22/2019)... ... May 22, 2019 , ... ... orthodontics solution to patients with crooked teeth in North Charleston, S.C. Using ... giving patients more discretion, flexibility, and confidence in the process of straightening ...
(Date:5/21/2019)... , ... May 22, 2019 , ... ... by FDAnews and ValSource, June 26-27, 2019 • Raleigh, NC, https://www.fdanews.com/cmo ... Interactive Workshop Presented by FDAnews and ValSource ends on May 31. , ...
(Date:5/21/2019)... ... May 21, 2019 , ... Dr. Mauricio Martinez and the team at Gulf ... as well as common symptoms to look out for including daytime fatigue and ... with sleep apnea and treats the condition with guided lifestyle changes, oral appliance therapy, ...
(Date:5/21/2019)... ... May 21, 2019 , ... CEO Steven C. ... the 24th annual Association of Corporate Growth Awards last week. ACG supports middle-market ... Brands, a leading dental support organization with over 400 affiliated practices across 17 ...
Breaking Medicine News(10 mins):